Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (1-10 of 824) with videos related to

Pageof 83
Sort By:
Critical Reviews in Immunology|February 1, 1981
B-lymphocyte ontogenyI Scher
Immunological Reviews|January 1, 1982
CBA/N immune defective mice; evidence for the failure of a B cell subpopulation to be expressedI Scher
Advances in Immunology|January 1, 1982
The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunityI Scher
The Journal of Urology|November 1, 1995
Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaborationH I Scher
Cephalalgia : an International Journal of Headache|July 17, 2009
Comment on Rubino et al., 'Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis'A I Scher
The Journal of Urology|November 1, 1992
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyH I Scher
The Urologic Clinics of North America|November 1, 1992
Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and resultsH I Scher
Journal of the National Cancer Institute|December 7, 2000
HER2 in prostate cancer--a viable target or innocent bystander?H I Scher
The Journal of Urology|August 1, 1994
High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladderH I Scher
The Journal of Urology|February 1, 1995
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5 year follow-upH I Scher
Pageof 83

Showing results (1-10 of 824) with videos related to

Sort By:
Pageof 83
Critical Reviews in Immunology|February 1, 1981
B-lymphocyte ontogenyI Scher
Immunological Reviews|January 1, 1982
CBA/N immune defective mice; evidence for the failure of a B cell subpopulation to be expressedI Scher
Advances in Immunology|January 1, 1982
The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunityI Scher
The Journal of Urology|November 1, 1995
Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaborationH I Scher
Cephalalgia : an International Journal of Headache|July 17, 2009
Comment on Rubino et al., 'Association of the C677T polymorphism in the MTHFR gene with migraine: a meta-analysis'A I Scher
The Journal of Urology|November 1, 1992
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group studyH I Scher
The Urologic Clinics of North America|November 1, 1992
Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and resultsH I Scher
Journal of the National Cancer Institute|December 7, 2000
HER2 in prostate cancer--a viable target or innocent bystander?H I Scher
The Journal of Urology|August 1, 1994
High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladderH I Scher
The Journal of Urology|February 1, 1995
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5 year follow-upH I Scher
Pageof 83